In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: West Pharmaceutical Services trades 53% above its high-confidence fair value average of $195, indicating potential overvaluation despite strong financial health. Monte Carlo analysis shows high downside risk with all scenarios below the current price and volatility at 45.6%. Valuation methods reveal divergence: conservative DCF estimates are much lower than analyst targets, suggesting differing growth assumptions.